Cytokine modulators as novel therapies for airway disease
暂无分享,去创建一个
[1] J. Kips,et al. Cytokines in asthma , 2001, European Respiratory Journal.
[2] I. Adcock,et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[3] R. Egan,et al. Th2 cytokines and asthma — The role of interleukin-5 in allergic eosinophilic disease , 2001, Respiratory research.
[4] J. Steinke,et al. Th2 cytokines and asthma — Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists , 2001, Respiratory research.
[5] R. Levitt,et al. Th2 cytokines and asthma — Interleukin-9 as a therapeutic target for asthma , 2001, Respiratory research.
[6] Stephen T Holgate,et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response , 2000, The Lancet.
[7] K. Chung,et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.
[8] P. Rutgeerts,et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .
[9] H. Sarau,et al. Identification of Potent, Selective Non-peptide CC Chemokine Receptor-3 Antagonist That Inhibits Eotaxin-, Eotaxin-2-, and Monocyte Chemotactic Protein-4-induced Eosinophil Migration* , 2000, The Journal of Biological Chemistry.
[10] Y. Nasuhara,et al. p38 MAP kinase and MKK‐1 co‐operate in the generation of GM‐CSF from LPS‐stimulated human monocytes by an NF‐κB‐independent mechanism , 2000, British journal of pharmacology.
[11] C. Power,et al. The strategy of blocking the chemokine system to combat disease , 2000, Immunological reviews.
[12] J. Gutiérrez-Ramos,et al. Non‐redundant functional groups of chemokines operate in a coordinate manner during the inflammatory response in the lung , 2000, Immunological reviews.
[13] I. Adcock,et al. Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.
[14] C. Dinarello. Interleukin-18, a proinflammatory cytokine. , 2000, European cytokine network.
[15] M. Peck,et al. A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.
[16] S. Sanjar,et al. Airway subepithelial fibrosis in a murine model of atopic asthma: suppression by dexamethasone or anti-interleukin-5 antibody. , 2000, American journal of respiratory cell and molecular biology.
[17] E. Tagaya,et al. Effect of suplatast tosilate, a Th2 cytokine inhibitor, on steroid-dependent asthma: a double-blind randomised study , 2000, The Lancet.
[18] P. Barnes,et al. New directions in allergic diseases: mechanism-based anti-inflammatory therapies. , 2000, The Journal of allergy and clinical immunology.
[19] A. Markham,et al. Infliximab: a review of its use in the management of rheumatoid arthritis. , 2000, Drugs.
[20] P. Rothman,et al. IL-4/IL-13 signaling beyond JAK/STAT. , 2000, The Journal of allergy and clinical immunology.
[21] H. Simon,et al. Treatment with IFN-a in corticosteroid-unresponsiveasthma , 2000 .
[22] D E Griswold,et al. Inhibition of p38 MAP kinase as a therapeutic strategy. , 2000, Immunopharmacology.
[23] P. Hiemstra,et al. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD , 2000, The Journal of pathology.
[24] R. Pauwels,et al. A long-term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. , 2000, American journal of respiratory and critical care medicine.
[25] P. Barnes,et al. Endogenous inhibitory mechanisms in asthma. , 2000, American journal of respiratory and critical care medicine.
[26] P. Barnes. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.
[27] P. Barnes,et al. Mechanisms in COPD: differences from asthma. , 2000, Chest.
[28] C. Martínez-A,et al. Cc Chemokine Receptor (Ccr)3/Eotaxin Is Followed by Ccr4/Monocyte-Derived Chemokine in Mediating Pulmonary T Helper Lymphocyte Type 2 Recruitment after Serial Antigen Challenge in Vivo , 2000, The Journal of experimental medicine.
[29] J. Lafitte,et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. , 2000, The Journal of allergy and clinical immunology.
[30] A. Zlotnik,et al. The biology of chemokines and their receptors. , 2000, Annual review of immunology.
[31] S. Erzurum,et al. Interleukin-9 Receptor Expression in Asthmatic Airways In Vivo , 2000, Lung.
[32] M. Humbert,et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.
[33] L. Borish,et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.
[34] P. Barnes. Therapeutic strategies for allergic diseases , 1999, Nature.
[35] R. Maciewicz,et al. New alpha-substituted succinate-based hydroxamic acids as TNFalpha convertase inhibitors. , 1999, Journal of medicinal chemistry.
[36] S. Wenzel,et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. , 1999, The Journal of clinical investigation.
[37] J. Gutiérrez-Ramos,et al. Eotaxin: from an eosinophilic chemokine to a major regulator of allergic reactions. , 1999, Immunology today.
[38] K. Chung,et al. Neutrophilic inflammation in severe persistent asthma. , 1999, American journal of respiratory and critical care medicine.
[39] R. Stockley,et al. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. , 1999, American journal of respiratory and critical care medicine.
[40] R. Strieter,et al. Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. , 1999, Journal of immunology.
[41] M. Adachi,et al. Effect of suplatast tosilate (IPD-1151T) on cytokine production by allergen-specific human Th1 and Th2 cell lines. , 1999, Life sciences.
[42] Y. Nasuhara,et al. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1beta and tumor necrosis factor-alpha in human U937 monocytic cells. Evidence for additional regulatory steps in kappaB-dependent transcription. , 1999, The Journal of biological chemistry.
[43] D. Faulds,et al. Etanercept: a review of its use in rheumatoid arthritis. , 1999, Drugs.
[44] K. Holroyd,et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. , 1999, The Journal of allergy and clinical immunology.
[45] S. Christensen,et al. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. , 1999, Pulmonary pharmacology & therapeutics.
[46] D. Hilton,et al. Cutting edge: SOCS-1 is a potent inhibitor of IL-4 signal transduction. , 1999, Journal of immunology.
[47] P. Barnes. Strategies for novel COPD therapies. , 1999, Pulmonary pharmacology & therapeutics.
[48] G. Hunninghake,et al. Both Erk and p38 kinases are necessary for cytokine gene transcription. , 1999, American journal of respiratory cell and molecular biology.
[49] T. Mosmann,et al. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. , 1999, Journal of immunology.
[50] D. Umetsu,et al. The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy. , 1999, The Journal of allergy and clinical immunology.
[51] P. Foster,et al. STAT6: an intracellular target for the inhibition of allergic disease. , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[52] D D Donaldson,et al. Interleukin-13: central mediator of allergic asthma , 1998 .
[53] K. Chung,et al. Inflammatory mediators of asthma: an update. , 1998, Pharmacological reviews.
[54] M. Kool,et al. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. , 1998, Journal of immunology.
[55] P. Barnes,et al. Inhibitory cytokines in asthma. , 1998, Molecular medicine today.
[56] L. Rosenwasser,et al. Biologic activities of IL-1 and its role in human disease. , 1998, The Journal of allergy and clinical immunology.
[57] J. Greve,et al. An immune cell-selective interleukin 4 agonist. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[58] P. Foster,et al. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. , 1998, Journal of immunology.
[59] C. Akdis,et al. Role of interleukin 10 in specific immunotherapy. , 1998, The Journal of clinical investigation.
[60] R. Hertzberg,et al. Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration* , 1998, The Journal of Biological Chemistry.
[61] M. M. Teixeira,et al. Effect of PDE4 inhibitors on zymosan‐induced IL‐8 release from human neutrophils: synergism with prostanoids and salbutamol , 1998, British journal of pharmacology.
[62] A. Luster,et al. Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.
[63] T. Torphy. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.
[64] J. Banchereau,et al. Interleukin-4 and interleukin-13: their similarities and discrepancies. , 1998, International reviews of immunology.
[65] C. Gabay,et al. Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.
[66] L Adorini,et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. , 1998, Annual review of immunology.
[67] K. Chung,et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. , 1998, American journal of respiratory and critical care medicine.
[68] C. Mackay,et al. Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co‐localization of eotaxin mRNA to bronchial epithelial and endothelial cells , 1997, European journal of immunology.
[69] A. Proudfoot,et al. The CC chemokine antagonist Met‐RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3 , 1997, European journal of immunology.
[70] S. Holgate,et al. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. , 1997, American journal of respiratory and critical care medicine.
[71] J. Leonard,et al. Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .
[72] S. Wenzel,et al. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.
[73] R. Martin,et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. , 1997, American journal of respiratory cell and molecular biology.
[74] T. Yoneda,et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. , 1997, Chest.
[75] L. Aarden,et al. Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma. , 1997, Journal of immunology.
[76] M. Goldman,et al. IL-10: a potential therapy for allergic inflammation? , 1997, Immunology today.
[77] J. Zurlinden. New treatments for asthma. , 1997, Nursing spectrum.
[78] S. Levy,et al. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. , 1997, Journal of immunology.
[79] M. Karin,et al. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.
[80] F. Finkelman,et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. , 1997, The American journal of physiology.
[81] P. Hogan,et al. Transcription factors of the NFAT family: regulation and function. , 1997, Annual review of immunology.
[82] J. Leonard,et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. , 1997, Blood.
[83] K. Chung,et al. Expression of RANTES mRNA and protein in airways of patients with mild asthma. , 1996, American journal of respiratory and critical care medicine.
[84] M. Cybulsky,et al. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. , 1996, The Journal of clinical investigation.
[85] A. Sousa,et al. Expression of interleukin-1 beta (IL-1beta) and interleukin-1 receptor antagonist (IL-1ra) on asthmatic bronchial epithelium. , 1996, American journal of respiratory and critical care medicine.
[86] E. Gelfand,et al. Nebulized IFN-gamma inhibits the development of secondary allergic responses in mice. , 1996, Journal of immunology.
[87] L. Fabbri,et al. Airway eosinophilia and expression of interleukin‐5 protein in asthma and in exacerbations of chronic bronchitis , 1996, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[88] S. Wenzel,et al. Interleukin-10 regulation in normal subjects and patients with asthma. , 1996, Journal of Allergy and Clinical Immunology.
[89] S. Durham,et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. , 1996, The Journal of allergy and clinical immunology.
[90] N. Barnes,et al. Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroid-dependent asthma. , 1996, American journal of respiratory and critical care medicine.
[91] R. Rogers,et al. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.
[92] P. Barnes,et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. , 1996, American journal of respiratory and critical care medicine.
[93] J. Bousquet,et al. Different cytokine patterns in bronchial biopsies in asthma and chronic bronchitis. , 1996, Respiratory medicine.
[94] R. Egan,et al. Biology of interleukin‐5 and its relevance to allergic disease , 1996, Allergy.
[95] J. Dayer,et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. , 1995, The Journal of clinical investigation.
[96] F. Finkelman,et al. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice , 1995, The Journal of experimental medicine.
[97] R. Egan,et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. , 1995, American journal of respiratory and critical care medicine.
[98] D. Leduc,et al. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. , 1995, The Journal of clinical investigation.
[99] Richard J Martin,et al. The effects of nebulized recombinant interferon-γ in asthmatic airways , 1995 .
[100] R. Egan,et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. , 1993, The American review of respiratory disease.
[101] R. Pauwels,et al. The potential role of tumour necrosis factor a in asthma , 1993, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.